Oncolys BioPharmaOncolys BioPharma Inc.4588東証グロース医薬品FY ending Dec 2025, non-consolidated, J-GAAP

What does Oncolys BioPharma do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

※ Operating cash flow is negative

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income-¥2.06B

Operating cash flow-¥1.94B

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow-¥1.94B

Free cash flow-¥1.94B

Net income-¥2.06B

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (6)

EDINET (FSA Japan)
有価証券報告書－第22期(2025/01/01－2025/12/31)
ID S100XTMG2026-03-25Open
EDINET (FSA Japan)
有価証券報告書－第21期(2024/01/01－2024/12/31)
ID S100VIBY2025-03-28Open
EDINET (FSA Japan)
有価証券報告書－第20期(2023/01/01－2023/12/31)
ID S100T65H2024-03-29Open
EDINET (FSA Japan)
有価証券報告書－第19期(2022/01/01－2022/12/31)
ID S100QI262023-03-30Open
EDINET (FSA Japan)
訂正有価証券報告書－第18期(令和3年1月1日－令和3年12月31日)
ID S100PNC22022-11-17Open
EDINET (FSA Japan)
有価証券報告書－第17期(令和2年1月1日－令和2年12月31日)
ID S100L1LQ2021-03-26Open

Extracted from XBRL: 40 / Derived from other figures: 2

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.